Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $12.05M rose 16.1% year over year, ahead of the +10.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +43.7% a year.

Context

  • Stock-based compensation amounted to 27.6% of revenue in FY2025, down 154.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.1% holds above the trailing-twelve-month pace of +10.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.05M+7.1% QoQ
Last fiscal yearDec 2025
$47.5M+10.4% YoY
LTMMar 2026
$49.18M+10.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.1%——
1 year+10.4%——
3-year CAGR+43.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
47.5M USD
Year-over-year change
+10.4%
4-year CAGR
+37.4%

Stock-Based Compensation vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's LTM Mar 2026 stock-based compensation of $49.18M is the 2nd largest of the 11 companies compared; the peer median is $28.9M.
  • Its year-over-year change of +10.5% is the 4th highest of 11, against a peer median of +1.4%.
  • Stock-based compensation amounts to 22.6% of revenue for SNDX, versus a peer median of 14.3%.
SNDX Competitors Peer median
Stock-Based Compensation for SNDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M -6.0%-2.6%53.8%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M +10.5%+43.7%22.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M +8.7%+10.5%5.8%
XNCRXencor, Inc.LTM Jun 2026$39.03M +10.2%-4.0%37.2%
ZYMEZymeworks Inc.LTM Sep 2026$37.94M +56.7%+91.1%14.3%
REPLReplimune Group, Inc.LTM Dec 2025$32.43M -6.5%+13.1%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$25.38M +66.4%——
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M -55.6%-11.3%8.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$9.87M -60.9%-19.2%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$9.12M +17.3%-21.7%25.6%
Peer median (excluding SNDX) $28.9M+1.4%-2.6%14.3%

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Depreciation & Amortization43K33K12K8K6K
Deferred Income Tax255K0000
Stock-Based Compensation13.32M16.02M30.95M43.03M47.5M
Change in Working Capital(9.6M)1.66M31.86M13.27M(79.32M)
Accounts Receivables0(3.47M)10.71M(11.24M)(36.83M)
Inventory03.47M0(366K)(32.09M)
Accounts Payables2.16M(1.32M)5.61M1.67M4.95M
Other Working Capital(11.76M)2.98M15.54M23.21M(15.35M)
Other Non-Cash Items187K(2.05M)(14.06M)(12.45M)(5.75M)
Operating Cash Flow29.13M(133.68M)(160.6M)(274.9M)(322.98M)
Capital Expenditures(129K)(225K)00(187K)
Acquisitions (Net)40.74K225K000
Purchases of Investments(294.72M)(495.35M)(354.61M)(557.05M)(195.81M)
Sales of Investments253.98M308.93M472.22M337.28M486.03M
Other Investing Activities(40.74K)225K000
Investing Cash Flow(40.87M)(186.19M)117.61M(219.78M)290.04M
Debt Repayment0(21M)000
Common Stock Issued86.34M181.39M258.09M9.72M13.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities32.13M11.86M6.04M343.65M0
Financing Cash Flow118.46M172.25M264.13M353.37M13.68M
Effect of Forex Changes00000
Net Change in Cash106.72M(147.61M)221.14M(141.31M)(19.27M)
Free Cash Flow29M(133.9M)(160.6M)(274.9M)(323.17M)

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.